🧠 Food for thought

Implications, context, and why it matters.

China’s performance comes from clinical use in everyday care

• The index tracks competitiveness through “regulated, clinically validated, and commercially scalable” biomedical solutions, rather than theory-heavy research output 1.
• One example comes from Puyang Prefecture in Henan province, where an AI-assisted ultrasound system reached 96.33% accuracy in spotting benign and malignant thyroid nodules. The case study said the AI rate was 20.72% above conventional methods 2.
• That same program raised consultation capacity at primary-level medical institutions from 20 to 25 patients a day to about 40. The study tied this to a 37.5% to 50% increase, as China pushes AI-assisted diagnosis and treatment in primary care nationwide by 2030 2.
• AI is also speeding up research work. Beijing Cancer Hospital used an AI system in a lung-cancer clinical-trial workflow that matched potential participants to trials overnight, then produced ranked options by the next morning 3.

Fast AI use in clinics brings legal questions for doctors

• China’s policy push in healthcare is reshaping the doctor-patient relationship into a “physician + AI–patient” model. That shift leaves legal duties and liability less clear 4.
• Legal scholars have proposed frameworks that tie accountability to how much decision-making power the AI holds. Their categories include tool-type, advisor-type, collaborative, and autonomous medical AI systems 4.
• The issue reaches beyond healthcare. Governments bringing AI into high-stakes industries may need governance rules at the same time as rollout, and Part 4 of the Index treats national AI policy, governance, and regulation as factors in competitiveness 5.